Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-B0257 |
Brand: | MCE |
CAS: | 797-63-7 |
MDL | - |
---|---|
Molecular Weight | 312.45 |
Molecular Formula | C21H28O2 |
SMILES | O=C1CC[C@]2([H])[C@@]3([H])CC[C@]4(CC)[C@@](C#C)(O)CC[C@@]4([H])[C@]3([H])CCC2=C1 |
Levonorgestrel is a synthetic progestogen used as an active ingredient in some hormonal contraceptives. Target: Progesterone Receptor A synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or (+-)-isomer (norgestrel). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. It is usually supplied in a racemic mixture (Norgestrel, 6533-00-2). Only the levonorgestrel isomer is active. Levonorgestrel is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Triphasil, and Min-Ovral [1].
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04972396 | Altimmune, Inc. |
NASH - Nonalcoholic Steatohepatitis
|
October 5, 2021 | Phase 1 |
NCT02357368 | Lisa Haddad|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Emory University |
HIV|Contraception
|
February 2015 | Phase 4 |
NCT00360490 | Bayer |
Menorrhagia
|
July 2006 | Phase 3 |
NCT01833793 | Bayer |
Female Contraception
|
February 2013 | |
NCT04142762 | Assembly Biosciences |
Chronic Hepatitis B
|
October 18, 2019 | Phase 1 |
NCT00551616 | HRA Pharma |
Contraception
|
April 2007 | Phase 3 |
NCT01623466 | Agile Therapeutics |
Healthy
|
July 2012 | Phase 1|Phase 2 |
NCT01414140 | Bayer |
Contraception
|
May 2007 | |
NCT01320917 | University of Sao Paulo |
Contraception Desired|Obesity
|
February 2009 | Phase 4 |
NCT01873170 | University of Pittsburgh |
HIV|Immune Cells (Mucosal and Systemic)|Contraception
|
August 2013 | |
NCT02531321 | University of Southern California |
Contraception|HIV
|
August 2015 | Phase 4 |
NCT01508858 | Novo Nordisk A+S |
Diabetes|Diabetes Mellitus, Type 2
|
November 2006 | Phase 1 |
NCT02173808 | Health Decisions|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Contraceptive Usage
|
May 2011 | Phase 1 |
NCT01096485 | Bayer |
Contraception|Contraception, Postcoital
|
February 2009 | Phase 1 |
NCT01240811 | Sharon Achilles|University of Pittsburgh |
Genital Tract Mucosal Immunity|Genital Tract Microflora
|
November 2010 | Not Applicable |
NCT02159131 | ViiV Healthcare |
Infections, Human Immunodeficiency Virus and Hepatitis
|
August 2014 | Phase 1 |
NCT01230242 | Rebecca Hunt|MaineHealth |
Estimating Rates of Expulsion
|
September 7, 2010 | Not Applicable |
NCT00781456 | Duramed Research|Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
January 2009 | Phase 2 |
NCT00204451 | University of Saskatchewan|Canadian Institutes of Health Research (CIHR) |
Contraception
|
July 2005 | Phase 4 |
NCT01963962 | University of Utah |
Emergency Contraception
|
July 2013 | |
NCT00868153 | Bayer |
Idiopathic Menorrhagia
|
August 2004 | |
NCT01595022 | Bayer |
Contraception
|
January 2010 | Phase 1 |
NCT04897217 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Endometrial Hyperplasia
|
January 2023 | Phase 3 |
NCT01297348 | Pfizer|Boston Collaborative Drug Surveillance Program |
Venous Thrombosis|Pulmonary Embolism|Sinus Thrombosis, Intracranial
|
July 2007 | |
NCT00924560 | Duramed Research|Teva Branded Pharmaceutical Products R&D, Inc. |
Bone Mineral Density
|
June 2009 | Phase 2 |
NCT05444582 | University of Utah|Planned Parenthood Federation of America |
Contraception
|
November 15, 2022 | |
NCT02002260 | Women and Infants Hospital of Rhode Island |
Abnormal Uterine Bleeding|Abnormal Uterine Bleeding, Ovulatory Dysfunction|Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
|
February 2013 | Not Applicable |
NCT00864136 | Bayer |
Menorrhagia
|
November 2008 | |
NCT01085487 | Bayer |
Idiopathic Menorrhagia
|
April 2009 | |
NCT03353012 | Chulalongkorn University |
Breastfeeding|Post Partum
|
January 1, 2018 | Phase 4 |
NCT03819114 | AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|Tuberculosis
|
May 6, 2019 | Phase 2 |
NCT02021097 | Regenex Pharmaceutical, China |
Oral Contraceptive
|
February 2012 | Phase 3 |
NCT03455075 | Health Decisions|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Washington |
Healthy|Men|Male Contraception
|
April 16, 2018 | Phase 2 |
NCT00922233 | FHI 360 |
Healthy
|
January 2010 | Phase 3 |
NCT02957292 | Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau|Bayer |
Contraception
|
June 1, 2016 | Phase 4 |
NCT00445887 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Carcinoma
|
March 10, 2008 | Phase 2 |
NCT04785950 | Bayer |
Hormonal Intrauterine Contraception
|
February 25, 2021 | |
NCT00621543 | Boston University|University of Utah |
Intrauterine Device Expulsion|Medical Abortion|Induced Abortion
|
March 2006 | Not Applicable |
NCT01539720 | Planned Parenthood of the St. Louis Region and Southwest Missouri|William and Flora Hewlett Foundation|University of Colorado, Denver|Planned Parenthood Federation of America|University of Rochester |
Pregnancy, Unplanned|Pregnancy; Accident
|
December 2012 | Not Applicable |
NCT01789879 | University of Nebraska|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Makerere University|University of Liverpool |
HIV|Contraception
|
June 2013 | Phase 2 |
NCT01328184 | Boehringer Ingelheim |
Healthy
|
April 2011 | Phase 1 |
NCT02104609 | University of Southern California|Society of Family Planning |
Obesity
|
April 2013 | |
NCT00271583 | University of Pittsburgh|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Emergency Contraception
|
September 1999 | Phase 2|Phase 3 |
NCT01291004 | Teva Branded Pharmaceutical Products R&D, Inc. |
Follicle Development|Ovarian Follicle|Follicle Count|Follicle Size|Oral Contraceptive
|
January 31, 2011 | Phase 1 |
NCT00455845 | Mahidol University |
Endometriosis|Pelvic Pain|Dysmenorrhea
|
April 2007 | Phase 3 |
NCT03359057 | Galeno Desenvolvimento de Pesquisas Clínicas|Biolab Sanus Farmaceutica |
Contraception
|
February 26, 2013 | Phase 3 |
NCT01731132 | Bayer |
Contraception
|
July 2012 | |
NCT00931827 | Bayer |
Contraception
|
January 2008 | |
NCT00131885 | University of Utah|National Center for Complementary and Integrative Health (NCCIH) |
Contraception
|
August 2005 | Phase 4 |
NCT04676776 | Gynuity Health Projects|Cuidado Integral de la Mujer, Gineclinic, S.C. |
Missed Menstrual Period
|
January 25, 2021 | Phase 2 |
NCT01250210 | Agile Therapeutics |
Ovulation Suppression
|
September 2007 | Phase 2 |
NCT02475356 | Bayer |
Menorrhagia, Dysmenorrhea
|
August 4, 2015 | |
NCT03537768 | Health Decisions|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Contraception
|
July 12, 2018 | Phase 4 |
NCT01590537 | Bayer |
Contraception
|
September 2011 | |
NCT01686126 | Queensland Centre for Gynaecological Cancer|The University of Queensland|Queensland University of Technology |
Complex Endometrial Hyperplasia With Atypia|Grade 1 Endometrial Endometrioid Adenocarcinoma
|
December 2012 | Phase 2 |
NCT00669396 | University of Utah |
Pregnancy
|
April 2008 | Not Applicable |
NCT02574715 | Bayer |
Quality of Life
|
September 18, 2015 | |
NCT05044962 | University of Washington|Moi Teaching and Referral Hospital|Indiana University|University of Nebraska|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|Contraception|Drug-drug Interaction
|
November 26, 2021 | Not Applicable |
NCT01721798 | FHI 360|University of Cape Town|City University of New York, School of Public Health |
HIV
|
November 10, 2013 | Not Applicable |
NCT01252186 | Teva Women´s Health|Teva Branded Pharmaceutical Products R&D, Inc. |
Hemostasis|Oral Contraceptive
|
November 2010 | Phase 2 |
NCT01166412 | Health Decisions|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Contraception
|
December 2010 | Phase 1|Phase 2 |
NCT00520455 | University of Washington|Centers for Disease Control and Prevention |
Pregnancy
|
January 2004 | Not Applicable |
NCT02362373 | Columbia University|Bayer |
Epilepsy|Contraception
|
August 2011 | Phase 4 |
NCT00570440 | FHI 360|La Asociación Pro Bienestar de la Familia de Guatemala (APROFAM) |
Pregnancy Prevention
|
August 2007 | Phase 4 |
NCT01044056 | Organon and Co |
Contraception
|
March 2004 | Phase 4 |
NCT00511355 | Organon and Co |
Contraception
|
October 2006 | Phase 3 |
NCT02403401 | Bayer |
Contraception
|
May 15, 2015 | Phase 3 |
NCT04230070 | Laboratorios Andromaco S.A. |
Bioequivalence
|
October 24, 2020 | Phase 1 |
NCT00490087 | IRCCS Burlo Garofolo |
Atypical Endometrial Polyps|Atypical Endometrial Hyperplasia
|
January 1999 | Phase 3 |
NCT00237042 | University of Washington|National Institute of Dental and Craniofacial Research (NIDCR) |
Temporomandibular Joint Disorders
|
October 2005 | Not Applicable |
NCT01990703 | University of Utah|Society of Family Planning|University of New Mexico |
Contraception
|
January 2014 | Phase 4 |
NCT04872244 | Gaziosmanpasa Research and Education Hospital |
Isthmocele|Post-menstrual Spotting Bleeding|Pelvic Pain
|
November 3, 2019 | Not Applicable |
NCT04385667 | Zagazig University |
Atypical Endometrial Hyperplasia
|
May 20, 2020 | Phase 2|Phase 3 |
NCT04194905 | Laboratorios Andromaco S.A. |
Bioequivalence
|
November 21, 2020 | Phase 1 |
NCT03249402 | Janssen-Cilag International NV |
Healthy
|
August 14, 2017 | Phase 1 |
NCT01074892 | University Hospital of North Norway|Helse Nord|Norwegian Cancer Society |
Endometrial Hyperplasia
|
May 2005 | Phase 4 |
NCT04814927 | Eastern Virginia Medical School|CONRAD|Kenya Medical Research Institute|United States Agency for International Development (USAID) |
Mucosal Inflammation|Contraceptive; Complications, Intrauterine
|
March 1, 2021 | Phase 4 |
NCT02903888 | Bayer |
Intrauterine Devices, Medicated
|
September 8, 2016 | |
NCT02556411 | University of Cagliari |
Adenomyosis|Chronic Pelvic Pain
|
June 1, 2021 | Not Applicable |
NCT01165307 | Abimbola Famuyide|Hologic, Inc.|Mayo Clinic |
Menorrhagia
|
August 2009 | Phase 4 |
NCT01501448 | IVI Madrid |
Infertility
|
January 2012 | Phase 4 |
NCT03642210 | Medicines360 |
Menorrhagia
|
January 17, 2019 | Phase 3 |
NCT00185380 | Bayer |
Contraception
|
April 2005 | Phase 2 |
NCT05343546 | Makerere University|Karolinska Institutet |
Incomplete Abortion|Intrauterine Contraception|Misoprostol
|
June 2022 | Not Applicable |
NCT00433004 | University of Pennsylvania |
Post Partum
|
February 2007 | Phase 4 |
NCT03660046 | Emory University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Hormonal Contraception
|
December 7, 2018 | |
NCT01088178 | United States Naval Medical Center, Portsmouth |
Contraception
|
November 2009 | Not Applicable |
NCT02577601 | Oregon Health and Science University|Society of Family Planning |
Contraception
|
September 8, 2015 | Phase 4 |
NCT01594476 | Oregon Health and Science University|Society of Family Planning |
Contraception
|
March 2012 | Phase 4 |
NCT01570244 | Boehringer Ingelheim |
Hepatitis C, Chronic
|
April 2012 | Phase 1 |
NCT00161226 | University of Medicine and Dentistry of New Jersey|Rutgers, The State University of New Jersey |
Endometrial Cancer
|
February 2004 | |
NCT01073904 | Bayer |
Contraceptives, Postcoital
|
September 2009 | Phase 1 |
NCT04058873 | Camber Collective|Population Council|Marie Stopes International|Bill and Melinda Gates Foundation|The Children´s Investment Fund Foundation |
Pregnancy Related
|
October 1, 2019 | |
NCT01157754 | IVI Madrid |
Infertility
|
June 2009 | Not Applicable |
NCT03074045 | Bayer |
Contraception
|
March 13, 2017 | Phase 3 |
NCT00874653 | Bayer |
Menorrhagia
|
April 2008 | |
NCT02121067 | University of North Carolina, Chapel Hill|Society of Family Planning |
Contraception|Malposition of Intrauterine Contraceptive Device
|
September 2014 | Phase 4 |
NCT02846142 | Proteostasis Therapeutics, Inc. |
Healthy Volunteer
|
June 2016 | Phase 1 |
NCT00248963 | Wyeth is now a wholly owned subsidiary of Pfizer |
Oral Contraceptive
|
Phase 3 | |
NCT00393198 | Bayer |
Contraception|Menorrhagia
|
October 2006 | Phase 4 |
NCT01096498 | Bayer |
Contraception|Contraception, Postcoital
|
February 2009 | Phase 1 |
NCT00245921 | Wyeth is now a wholly owned subsidiary of Pfizer |
Contraception
|
February 2003 | Phase 3 |
NCT00909857 | Bayer |
Primary Dysmenorrhea
|
April 2009 | Phase 3 |
NCT02722421 | University of Nebraska|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Infectious Diseases Institute, Uganda|University of Liverpool|Northwestern University Feinberg School of Medicine |
HIV|Contraception
|
April 6, 2017 | Phase 2 |
NCT02599077 | Fundación Santa Fe de Bogota |
Endometriosis
|
November 2015 | Phase 2|Phase 3 |
NCT02203331 | Bayer |
Endometriosis
|
October 16, 2014 | Phase 2 |
NCT02480647 | University of Campinas, Brazil |
Endometriosis
|
May 2016 | Phase 4 |
NCT02985541 | Bayer |
Contraception
|
December 22, 2016 | Phase 3 |
NCT00302848 | Center for Epidemiology and Health Research, Germany|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma |
Contraception
|
November 2000 | |
NCT00254189 | Wyeth is now a wholly owned subsidiary of Pfizer |
Ovulation
|
December 2002 | Phase 2 |
NCT00884260 | Bayer |
Contraception
|
April 2009 | Phase 3 |
NCT01286948 | Population Council |
Female Contraception
|
January 2011 | Phase 1 |
NCT03317795 | Shannon K. Laughlin-Tommaso|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Mayo Clinic |
Heavy Menstrual Bleeding|Menorrhagia|Uterine Fibroids
|
November 14, 2017 | Phase 4 |
NCT01254292 | Bayer |
Contraception
|
January 6, 2011 | Phase 3 |
NCT00475228 | University of Pittsburgh |
Contraceptive Usage
|
March 2007 | Phase 4 |
NCT03614494 | Dr. Hang Wun Raymond Li|The Family Planning Association of Hong Kong|The University of Hong Kong |
Emergency Contraception
|
August 20, 2018 | Phase 2|Phase 3 |
NCT02158845 | University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico |
Endometriosis
|
February 2010 | Phase 4 |
NCT02545452 | Bayer |
Endometriosis
|
September 15, 2015 | Phase 1 |
NCT02349815 | Bayer|Karolinska Institutet, Stockholm, Sweden |
Contraception
|
January 1, 2017 | |
NCT01958684 | Bayer |
Contraception
|
October 2013 | |
NCT03305081 | Tulane University School of Medicine|Tulane University |
Contraception
|
October 22, 2014 | Not Applicable |
NCT05282940 | Laboratorios Andromaco S.A. |
Therapeutic Equivalency
|
February 26, 2022 | Phase 1 |
NCT00662454 | Oregon Health and Science University|National Institutes of Health (NIH)|Oregon Clinical and Translational Research Institute |
Contraception|Body Weight
|
January 2006 | Phase 4 |
NCT03589027 | Makerere University|University of Nebraska|University of Pittsburgh|University of Liverpool |
HIV-1-infection|Contraception
|
August 7, 2018 | Phase 2 |
NCT00685906 | AstraZeneca |
Healthy
|
April 2008 | Phase 1 |
NCT04143659 | Health Decisions|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Healthy Women|Female Contraception
|
March 3, 2020 | Phase 1 |
NCT03104309 | Assiut University |
Adenomyosis
|
June 2015 | Not Applicable |
NCT04910711 | Botswana Harvard AIDS Institute Partnership|University of Liverpool |
Human Immunodeficiency Virus|Contraception|ART
|
October 21, 2021 | Phase 4 |
NCT00883662 | Bayer |
Contraception|Menorrhagia|Endometrial Hyperplasia|Estrogen Replacement Therapy
|
May 2009 | |
NCT00966771 | University of Utah|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Society of Family Planning |
Pregnancy
|
October 2009 | |
NCT02175030 | University of Utah |
Contraception
|
August 2016 | Phase 4 |
NCT03778359 | Taipei Veterans General Hospital, Taiwan |
Endometriosis|Adenomyosis
|
January 1, 2005 | |
NCT05093205 | Pfizer |
Healthy Adults
|
October 25, 2021 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 320.05 mM ; ultrasonic and warming and heat to 60°C)
H 2 O : < 0.1 mg/mL (insoluble)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.2005 mL | 16.0026 mL | 32.0051 mL |
5 mM | 0.6401 mL | 3.2005 mL | 6.4010 mL |
10 mM | 0.3201 mL | 1.6003 mL | 3.2005 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.